共 2 条
[1]
2013, N ENGL J MED, V369, P1779
[2]
2013, N ENGL J MED, V369, P1783
Ariad Suspends Ponatinib Sales
被引：5
作者：
不详
机构：
关键词：
D O I：
10.1158/2159-8290.CD-NB2013-163
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Because of concerns about serious cardiovascular side effects, the U.S. Food and Drug Administration asked Ariad Pharmaceuticals to temporarily suspend sales and marketing of ponatinib to treat chronic myeloid leukemia in patients resistant to first-line therapy.
引用
收藏
页码：6 / 7
页数：2
相关论文